EGFR and non-small cell lung carcinoma: Recent data have shown that curatively resected EGFR-mutation-positive NSCLC patients in stages IB–IIIA may benefit from adjuvant therapy with tyrosine kinase inhibitors (TKIs) [6,7,8].